Featured Articles

  1. A New Avenue In Breast Cancer Therapeutics 1/23/2023

    Clinical trial findings may have unlocked a groundbreaking opportunity for breast cancer patients: beneficial therapy for HER2-negative patients with HER2-directed antibody-drug conjugates.

  2. 3 Data Linkage Use Cases To Future Proof Your Clinical Trials 12/20/2022

    Discover why access to compelling and relevant evidence is crucial to drug development, safety monitoring, and improved patient outcomes. 

  3. The Future Of Data Linkage In Clinical Trial Evidence Generation 12/20/2022

    Explore key questions about the future of AI and data linkage in clinical trial evidence generation.

  4. The Regulatory Grade External Control Arm To Power Your Clinical Trials 12/9/2022

    Examine the growing role of external control arms in clinical trials, including the distinctions between control groups that use real-world data and those that use historical clinical trial data.

  5. Imunon Phase IB Ovarian Cancer Study Shows Strong Progression-Free Survival Treatment Effect Using A Synthetic Control Arm 12/8/2022

    Explore how Imunon used a control arm among stage III/IV ovarian cancer patients in their clinical trial.

  6. A Mid-Sized Sponsor Increased Site Count By 50% In A Rare Disease Clinical Trial 12/8/2022

    In this case study, explore how a mid-sized sponsor chose high-performing sites based on reliable data to set their trial up for success.

  7. Medicenna Gains Precedent-Setting FDA Approval 12/8/2022

    Learn how Medicenna was able to leverage Synthetic Control Arm (SCA) to bolster Phase 2 findings and gain FDA approval to design a hybrid external control arm for their Phase 3 registrational trial.

  8. Synthetic Control Arm In Clinical Trials 12/8/2022

    Get an overview of the SCA, an external control generated with the goal of improving the interpretation of uncontrolled trials, which can enable better product development decisions.

  9. Site Perspectives On Decentralized Clinical Trials 11/15/2022

    Discover why understanding clinical research sites’ experiences and perspectives on DCTs will help industry stakeholders  refine trial design, operational procedures, and regulatory policy to better serve patients and sites.

  10. Predictors Of Severe CRS In Longitudinal CAR T-Cell Clinical Trial Data 9/15/2022

    Find out how laboratory tests were analyzed with repeated measurements to identify differences in trends that persist across a variety of study designs, sponsors, and indications.